Umbilical cord blood mesenchymal stem cells as an infertility treatment for chemotherapy induced premature ovarian insufficiency

Sara A. Mohamed, Shahinaz Shalaby, Soumia Brakta, Lelyand Elam, Amro Elsharoud, Ayman Al-Hendy

Research output: Contribution to journalArticle

Abstract

Background: Premature ovarian insufficiency (POI) is a challenging disease, with limited treatment options at the moment. Umbilical cord blood mesenchymal stem cells (UCMSCs) have demonstrated promising regenerative abilities in several diseases including POI. Materials and Method: A pre-clinical murine case versus vehicle control randomized study. Two experiments ran in parallel in each of the three groups. The first was to prove the ability of UCMSCs in restoring ovarian functions. The second was to prove improved fertility. A total of 36 mice were randomly assigned; 6 mice into each of 3 groups for two experiments. Group 1 (control), group 2 (sham chemotherapy), group 3 (stem cells). Results: In the first experiment, post-UCMSCs treatment (group 3) showed signs of restored ovarian function in the form of increased ovarian weight and estrogen-dependent organs (liver, uterus), increased follicular number, and a significant decrease in FSH serum levels (p < 0.05) compared to group 2, and anti-Mullerian hormone (AMH) serum levels increased (p < 0.05) in group 3 versus group 2. Immuno-histochemistry analysis demonstrated a higher expression of AMH, follicle stimulating hormone receptor (FSHR) and Inhibin A in the growing follicles of group 3 versus group 2. In the second experiment, post-UCMSCs treatment (group 3) pregnancy rates were higher than group 2, however, they were still lower than group 1. Conclusion: We demonstrated the ability of UCMSCs to restore fertility in female cancer survivors with POI and as another source of stem cells with therapeutic potentials.

Original languageEnglish (US)
Article number7
JournalBiomedicines
Volume7
Issue number1
DOIs
StatePublished - Mar 1 2019

Fingerprint

Chemotherapy
Stem cells
Mesenchymal Stromal Cells
Fetal Blood
Infertility
Blood
Drug Therapy
Anti-Mullerian Hormone
Fertility
Stem Cells
FSH Receptors
Therapeutics
Experiments
Pregnancy Rate
Serum
Uterus
Survivors
Estrogens
Liver
Weights and Measures

Keywords

  • Chemotherapy
  • Ovarian failure
  • Stem cells

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Umbilical cord blood mesenchymal stem cells as an infertility treatment for chemotherapy induced premature ovarian insufficiency. / Mohamed, Sara A.; Shalaby, Shahinaz; Brakta, Soumia; Elam, Lelyand; Elsharoud, Amro; Al-Hendy, Ayman.

In: Biomedicines, Vol. 7, No. 1, 7, 01.03.2019.

Research output: Contribution to journalArticle

Mohamed, Sara A. ; Shalaby, Shahinaz ; Brakta, Soumia ; Elam, Lelyand ; Elsharoud, Amro ; Al-Hendy, Ayman. / Umbilical cord blood mesenchymal stem cells as an infertility treatment for chemotherapy induced premature ovarian insufficiency. In: Biomedicines. 2019 ; Vol. 7, No. 1.
@article{81315c1f3c964a0f8f9d52017aa672c3,
title = "Umbilical cord blood mesenchymal stem cells as an infertility treatment for chemotherapy induced premature ovarian insufficiency",
abstract = "Background: Premature ovarian insufficiency (POI) is a challenging disease, with limited treatment options at the moment. Umbilical cord blood mesenchymal stem cells (UCMSCs) have demonstrated promising regenerative abilities in several diseases including POI. Materials and Method: A pre-clinical murine case versus vehicle control randomized study. Two experiments ran in parallel in each of the three groups. The first was to prove the ability of UCMSCs in restoring ovarian functions. The second was to prove improved fertility. A total of 36 mice were randomly assigned; 6 mice into each of 3 groups for two experiments. Group 1 (control), group 2 (sham chemotherapy), group 3 (stem cells). Results: In the first experiment, post-UCMSCs treatment (group 3) showed signs of restored ovarian function in the form of increased ovarian weight and estrogen-dependent organs (liver, uterus), increased follicular number, and a significant decrease in FSH serum levels (p < 0.05) compared to group 2, and anti-Mullerian hormone (AMH) serum levels increased (p < 0.05) in group 3 versus group 2. Immuno-histochemistry analysis demonstrated a higher expression of AMH, follicle stimulating hormone receptor (FSHR) and Inhibin A in the growing follicles of group 3 versus group 2. In the second experiment, post-UCMSCs treatment (group 3) pregnancy rates were higher than group 2, however, they were still lower than group 1. Conclusion: We demonstrated the ability of UCMSCs to restore fertility in female cancer survivors with POI and as another source of stem cells with therapeutic potentials.",
keywords = "Chemotherapy, Ovarian failure, Stem cells",
author = "Mohamed, {Sara A.} and Shahinaz Shalaby and Soumia Brakta and Lelyand Elam and Amro Elsharoud and Ayman Al-Hendy",
year = "2019",
month = "3",
day = "1",
doi = "10.3390/biomedicines7010007",
language = "English (US)",
volume = "7",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "MDPI AG",
number = "1",

}

TY - JOUR

T1 - Umbilical cord blood mesenchymal stem cells as an infertility treatment for chemotherapy induced premature ovarian insufficiency

AU - Mohamed, Sara A.

AU - Shalaby, Shahinaz

AU - Brakta, Soumia

AU - Elam, Lelyand

AU - Elsharoud, Amro

AU - Al-Hendy, Ayman

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: Premature ovarian insufficiency (POI) is a challenging disease, with limited treatment options at the moment. Umbilical cord blood mesenchymal stem cells (UCMSCs) have demonstrated promising regenerative abilities in several diseases including POI. Materials and Method: A pre-clinical murine case versus vehicle control randomized study. Two experiments ran in parallel in each of the three groups. The first was to prove the ability of UCMSCs in restoring ovarian functions. The second was to prove improved fertility. A total of 36 mice were randomly assigned; 6 mice into each of 3 groups for two experiments. Group 1 (control), group 2 (sham chemotherapy), group 3 (stem cells). Results: In the first experiment, post-UCMSCs treatment (group 3) showed signs of restored ovarian function in the form of increased ovarian weight and estrogen-dependent organs (liver, uterus), increased follicular number, and a significant decrease in FSH serum levels (p < 0.05) compared to group 2, and anti-Mullerian hormone (AMH) serum levels increased (p < 0.05) in group 3 versus group 2. Immuno-histochemistry analysis demonstrated a higher expression of AMH, follicle stimulating hormone receptor (FSHR) and Inhibin A in the growing follicles of group 3 versus group 2. In the second experiment, post-UCMSCs treatment (group 3) pregnancy rates were higher than group 2, however, they were still lower than group 1. Conclusion: We demonstrated the ability of UCMSCs to restore fertility in female cancer survivors with POI and as another source of stem cells with therapeutic potentials.

AB - Background: Premature ovarian insufficiency (POI) is a challenging disease, with limited treatment options at the moment. Umbilical cord blood mesenchymal stem cells (UCMSCs) have demonstrated promising regenerative abilities in several diseases including POI. Materials and Method: A pre-clinical murine case versus vehicle control randomized study. Two experiments ran in parallel in each of the three groups. The first was to prove the ability of UCMSCs in restoring ovarian functions. The second was to prove improved fertility. A total of 36 mice were randomly assigned; 6 mice into each of 3 groups for two experiments. Group 1 (control), group 2 (sham chemotherapy), group 3 (stem cells). Results: In the first experiment, post-UCMSCs treatment (group 3) showed signs of restored ovarian function in the form of increased ovarian weight and estrogen-dependent organs (liver, uterus), increased follicular number, and a significant decrease in FSH serum levels (p < 0.05) compared to group 2, and anti-Mullerian hormone (AMH) serum levels increased (p < 0.05) in group 3 versus group 2. Immuno-histochemistry analysis demonstrated a higher expression of AMH, follicle stimulating hormone receptor (FSHR) and Inhibin A in the growing follicles of group 3 versus group 2. In the second experiment, post-UCMSCs treatment (group 3) pregnancy rates were higher than group 2, however, they were still lower than group 1. Conclusion: We demonstrated the ability of UCMSCs to restore fertility in female cancer survivors with POI and as another source of stem cells with therapeutic potentials.

KW - Chemotherapy

KW - Ovarian failure

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=85063569409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063569409&partnerID=8YFLogxK

U2 - 10.3390/biomedicines7010007

DO - 10.3390/biomedicines7010007

M3 - Article

AN - SCOPUS:85063569409

VL - 7

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 1

M1 - 7

ER -